Visual Abstract

Intro: In 2016 the FDA changed metformin’s label to allow initiation at estimated glomerular filtration rate levels of ≥ 45 mL/min/1.73 m2. We sought to determine trends of incident metformin for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) from 2010-2018.

Methods: We assessed trends of new metformin prescriptions in treatment naïve patients with T2DM and CKD from the Veterans Affairs from 2010-2018. Incidence was calculated as the number of new metformin prescriptions per 1,000 eligible patients.

Results: A total of 616,670 patients were eligible. Patients had a mean age of 68 (SD 11.1), 95.8% were male, and 72.2% were white. Figure 1 displays trends in the total cohort. Figure 2 displays trends by CKD stage.

Discussion: There was increased trend in new metformin prescriptions predominately in stages 3a and 3b.

Disclosure

C. A. Alvarez: None. A. Perkins: None. L. Gregg: None. E. Mortensen: None.

Funding

National Institutes of Health (K08DK101602)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.